Profile
TAK ZTS HLN TEVA ITCI CTLT
Company Name Takeda Pharmaceutical Company Limited Zoetis Inc. Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc. Catalent, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $48.16B $73.21B $45.90B $15.81B $14.00B $11.52B
Employees 49.28K 13.80K 24.56K 33.89K 0.86K 17.00K
CEO Mr. Christophe Weber Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Richard D. Francis Dr. Sharon Mates Ph.D. Mr. Alessandro Maselli
Ratings
Trading
TAK ZTS HLN TEVA ITCI CTLT
Last Close $14.72 $151.73 $9.89 $13.8 $131.87 $63.48
High 52 $15.19 $196.48 $10.69 $22.77 $131.91 $63.48
Low 52 $12.6 $145.54 $8.01 $12.78 $64.76 $53.58
Price vs. 52 Week High -3.09 % -22.78 % -7.48 % -39.39 % -0.03 % 0 %
Price vs. 52 Week Low 16.83 % 4.25 % 23.47 % 7.98 % 103.63 % 18.48 %
Total Return
TAK ZTS HLN TEVA ITCI CTLT
1 Month Return -1.87 % -9.28 % -4.81 % -10.1 % 0.47 % 0 %
3 Month Return 10.68 % -8.54 % 4.66 % -34.5 % 61.25 % 0 %
6 Month Return 2.01 % -20.15 % -4.63 % -21.1 % 80.92 % 4.77 %
9 Month Return 11.43 % -13.28 % 16.77 % -15.85 % 89.58 % 11.9 %
YTD Return 11.18 % -6.87 % 3.67 % -37.39 % 57.89 % 0 %
1 Year Return 8.08 % -8.52 % 19.3 % -3.16 % 92.68 % 11.86 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
TAK ZTS HLN TEVA ITCI CTLT
Dividend Yield Percentage (TTM) 4.23 % 1.1 % 0.01 % - - -
Dividend Paid and Capex Coverage Ration (TTM) 1.76 % 2.05 % - 2.5 % -227.26 % 1.33 %
Dividend Per Share (TTM) 192 % 1.8 % 0.02 % - - -
Payout Ratio (TTM) 145.09 % 31.62 % - - - -
Growth
TAK ZTS HLN TEVA ITCI CTLT
Asset Growth 8.25 % -0.34 % 0.76 % -9.55 % -9.54 %
Gross Profit Growth 1.76 % 12.05 % -0.19 % 5.47 % -10.09 %
Revenue Growth 5.87 % 8.33 % -0.61 % 4.4 % 2.46 %
Revenue 3 Year 33.13 % 24.31 % 18.32 % 1.52 % 1.71 %
Revenue 5 Year 103.83 % 55.65 % 33.18 % -5.5 % 38.66 %
Revenue 10 Year 152.69 % 113.39 % 33.18 % -38.45 % 55.34 %
EBIT Growth -56.36 % 103.71 % 10.52 % -169.98 % -446.72 %
Net Income Growth -54.56 % 6.06 % 37.46 % -193.2 % -349.57 %
Net Income 3 Yeari Growth Per Share -61.74 % 27.46 % 4.3 % -482.97 % -265.49 %
Net Income 5 Yeari Growth Per Share 32.36 % 74.46 % 121.35 % -58.26 % -704.95 %
Net Income 10 Yeari Growth Per Share 35.42 % 370.4 % 121.35 % -140.46 % -4272.48 %
Operating Income Growth -56.36 % 103.71 % 10.52 % -169.98 % -446.72 %
Operating Cash Flow Growth (CFG) -26.69 % 25.5 % 9.57 % -8.85 % 2.68 %
Operating 3 Year CFG -29.25 % 39.36 % 70.61 % 52.26 % -42.55 %
Operating 5 Year CFG 118.64 % 73.18 % 194.34 % 123.59 % -13.77 %
Operating 10 Year CFG 384.17 % 420.39 % 194.34 % -81.66 % -2.59 %
EPS Growth -54.92 % 7.68 % 45.45 % -190 % -350 %
EPS Diluted Growth -54.86 % 7.89 % 45.45 % -190 % -350 %
Book Value Per Share 13.54 % -2.96 % -2.19 % -30.36 % -22.24 %
Share Holder 3 Year Equity Growth Per Share 40.38 % 9.65 % -38.33 % -49 % -14.56 %
Share Holder 5 Year Equity Growth Per Share 41.33 % 85.42 % -40.51 % -62.86 % 70.8 %
Share Holder 10 Year Equity Growth Per Share 195.14 % 301.38 % -40.51 % -82.6 % 728.2 %
Dividend Per Share Growth 1.95 % 15.33 % 48.16 % - -
Dividend 3 Year Growth Per Share 1.19 % 73.18 % -50.08 % - -100 %
Dividend 5 Year Growth Per Share 101.42 % 163.51 % -50.25 % -100 % -
Dividend 10 Year Growth Per Share 102.58 % 493.89 % -50.25 % -100 % -
Debt Growth 10.53 % -0.16 % 8.79 % -10.29 % 1.42 %
Free Cash Flow Growth -31.4 % 41.76 % 16.27 % -11.05 % 81.68 %
Updated On 31 Mar 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024 30 Jun 2024
Profitability
TAK ZTS HLN TEVA ITCI CTLT
Gross Profit Margin TTM 54.74 % 69.85 % 61.52 % 48.74 % 91.63 % 21.82 %
Return on Assets TTM 1.38 % 17.46 % 4.2 % -4.17 % -5.46 % -4.25 %
Return on Equity TTM 2.83 % 49.65 % 8.73 % -26.15 % -7.4 % -11.44 %
Return on Capital Employed TTM 3.62 % 24.27 % 7.74 % -1.14 % -10.05 % 0.64 %
Net Income Per EBT TTM 89.75 % 79.35 % 75.5 % 127.75 % 100.64 % 119.02 %
EBT Per Ebit TTM 49.18 % 119.26 % 86.58 % 423.43 % 63.57 % -619.64 %
EBIT Per Revenue TTM 10.3 % 28.38 % 19.64 % -1.83 % -17.15 % 1.27 %
Cash Flow To Debt Ratio TTM 22.2 % 43.79 % - 6.9 % -430.93 % 8.09 %
Receivables Turnover TTM 6.23 7.03 - 5.41 4.09 3.03
Payables Turnover TTM 4.5 6.45 2.19 3.85 2.18 9.22
Inventory Turnover TTM 1.66 1.21 3.63 2.82 2.17 6.25
Fixed Asset Turnover TTM 226.93 % 256.4 % 584.75 % 334.34 % 4569.25 % 120.46 %
Asset Turnover TTM 30.31 % 65.01 % 32.73 % 42.07 % 49.79 % 45.55 %
Operating Cash Flow Per Share TTM 678.77 6.5 - 1.1 -0.71 2.19
Free Cash Flow Per Share TTM 484.07 5.06 - 0.66 -0.71 0.54
Cash Per Share TTM 33271.95 % 437.03 % 24.05 % 291.26 % 970.67 % 184.07 %
Operating Cash Flow Sales Ratio TTM 23.47 % 31.9 % - 7.54 % -10.75 % 9.02 %
Free Cash Flow Operating Cash Flow Ratio TTM 71.32 % 77.82 % - 60.06 % 100.44 % 24.81 %
Cash Flow Coverage Ratios TTM 22.2 % 43.79 % - 6.9 % -430.93 % 8.09 %
Price To Free Cash Flows Ratio TTM 9.39 31.86 - 21.46 -190.53 116.39
Price To Operating Cash Flows Ratio TTM 6.69 25.15 - 12.75 -185.61 28.96
Price Cash Flow Ratio TTM 6.69 25.15 - 12.75 -185.61 28.96
Income Statement (TTM)
TAK ZTS HLN TEVA ITCI CTLT
Revenue $4263.76B $9.26B $11.23B $16.54B $0.68B $4.38B
Gross Profit $2832.26B $6.54B $6.95B $8.06B $0.62B $0.95B
Gross Profit Ratio 66.43% 70.62% 61.85% 48.74% 91.63% 21.8%
EBITDA $874.6B $3.86B $2.51B $-0.3B $-0.12B $-0.28B
Net Income $144.07B $2.49B $1.44B $-1.64B $-0.07B $-1.04B
EPS Diluted 91.16 5.47 0.16 -1.45 -0.72 -5.76
Balance Sheet (MRQ)
TAK ZTS HLN TEVA ITCI CTLT
Long Term Debt $5029.93B $5.39B $8.71B $16.3B $0.01B $4.86B
Total Liabilities $7834.79B $9.47B $18.09B $33.61B $0.22B $6.15B
Total Equity $7274.01B $4.77B $16.22B $5.72B $1.15B $3.6B
Total Investments $445.7B $0B $0.08B $0B $0.69B $0.16B
Total Debt $4843.75B $6.74B $10.29B $18.08B $0.02B $4.92B
Total Assets $15108.79B $14.24B $34.32B $39.33B $1.37B $9.75B
Cash Flow Statement (TTM)
TAK ZTS HLN TEVA ITCI CTLT
Net Income $144.07B $2.5B $1.44B $-1.96B $-0.07B $-1.04B
Inventory $-115.74B $-0.04B $0.22B $0.17B $-0.01B $0.11B
Dividends Paid $-287.19B $-0.79B $-0.57B $0B $0B $0B
Operating Cash Flow $716.34B $2.95B $2.3B $1.25B $-0.07B $0.27B
Capital Expenditure $-480.73B $-0.66B $-0.25B $-0.5B $-0B $-0.33B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.015
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.22
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 8.5
ALVOW Alvotech 1.11
AMPH Amphastar Pharmaceuticals, Inc. 26.61
AMRX Amneal Pharmaceuticals, Inc. 7.38
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 67.52
AQST Aquestive Therapeutics, Inc. 2.71
ASRT Assertio Holdings, Inc. 0.6272
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 6.8
AYTU Aytu BioPharma, Inc. 1.03
ETFs With Exposure to TAK
Unlock